117516-97-9

Usage

Uses

Used in Pharmaceutical Industry:
2-Thioxo-2,3-dihydrothieno[2,3-d]pyrimidin-4(1H)-one is used as a starting material for the synthesis of various drugs and bioactive compounds. Its unique structural features and biological activities make it a valuable component in the development of new pharmaceuticals.
Used in Antitumor Applications:
2-Thioxo-2,3-dihydrothieno[2,3-d]pyrimidin-4(1H)-one is used as an antitumor agent due to its promising antitumor activities. It has the potential to be further developed and optimized for use in cancer treatment, targeting various types of tumors and contributing to the advancement of oncology.
Used in Antiviral Applications:
2-Thioxo-2,3-dihydrothieno[2,3-d]pyrimidin-4(1H)-one is used as an antiviral agent, exhibiting potential in the development of treatments for viral infections. Its antiviral properties make it a candidate for further research and development in the field of virology and infectious diseases.
Used in Medicinal Chemistry Research:
2-Thioxo-2,3-dihydrothieno[2,3-d]pyrimidin-4(1H)-one is used as a subject of research in medicinal chemistry. Its unique structure and biological activities make it an important compound for understanding the relationship between chemical structure and biological function, as well as for the discovery of new therapeutic agents.

Upstream product

• 14080-51-4 2-aminothiophene-3-carboxamide 
• 140-89-6 potassium ethyl xanthogenate 
• 2720-67-4 potassium propylxanthate 
• 31891-06-2 ethyl 2-aminothiophene-3-carboxylate 
• 4651-81-4 Methyl 2-aminothiophene-3-carboxylate 

Downstream Products

• 309976-36-1 2-(methylthio)thieno[2,3-d]pyrimidin-4(3H)-one 
• 1312701-38-4 (E)-2-(2-benzylidenehydrazinyl)thieno[2,3-d]pyrimidin-4(3H)-one 
• 1312701-39-5 (E)-2-(2-(4-chlorobenzylidene)hydrazinyl)thieno[2,3-d]pyrimidin-4(3H)-one 
• 1312701-40-8 (E)-2-(2-(4-methoxybenzylidene)hydrazinyl)thieno[2,3-d]pyrimidin-4(3H)-one 
• 1312701-41-9 (E)-2-(2-(4-bromobenzylidene)hydrazinyl)thieno[2,3-d]pyrimidin-4(3H)-one 
• 1312701-42-0 (E)-2-(2-(4-methylbenzylidene)hydrazinyl)thieno[2,3-d]pyrimidin-4(3H)-one 
• 1312701-43-1 (E)-2-(2-(3-chlorobenzylidene)hydrazinyl)thieno[2,3-d]pyrimidin-4(3H)-one 
• 1312701-44-2 (E)-2-(2-(3-bromobenzylidene)hydrazinyl)thieno[2,3-d]pyrimidin-4(3H)-one 
• 1312701-45-3 (E)-2-(2-(3-methylbenzylidene)hydrazinyl)thieno[2,3-d]pyrimidin-4(3H)-one 
• 1312701-54-4 1-phenylthieno[3,2-e][1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-one 
• 1312701-55-5 1-(4-chlorophenyl)thieno[3,2-e][1,2,4]triazolo[4,3-a]pyramidin-5(4H)-one 
• 1312701-56-6 1-(4-methoxyphenyl)thieno[3,2-e][1,2,4]triazolo[4,3-a]pyramidin-5(4H)-one 
• 1312701-57-7 1-(4-bromophenyl)thieno[3,2-e][1,2,4]triazolo[4,3-a]pyramidin-5(4H)-one 
• 1312701-58-8 1-p-tolylthieno[3,2-e][1,2,4]triazolo[4,3-a]pyramidin-5(4H)-one 

Relevant academic research and scientific papers

Development of matrix metalloproteinase-13 inhibitors – A structure-activity/structure-property relationship study

A structure-activity/structure-property relationship study based on the physicochemical as well as in vitro pharmacokinetic properties of a first generation matrix metalloproteinase (MMP)-13 inhibitor (2) was undertaken. After systematic variation of inhi

Photooxygenation of an amino-thienopyridone yields a more potent PTP4A3 inhibitor

The phosphatase PTP4A3 is an attractive anticancer target, but knowledge of its exact role in cells remains incomplete. A potent, structurally novel inhibitor of the PTP4A family was obtained by photooxygenation of a less active, electron-rich thienopyrid

Synthesis of new 1-phenylthieno[1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-one derivatives

A series of novel 1-phenylthieno[1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-one derivatives 5 and 6 were synthesized by oxidative cyclization of thienopyrimidinonyl hydrazones using iodobenzene diacetate.

Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2/su

Bicyclic pyridine and pyrimidine p38 kinase inhibitors

The present invention discloses compounds corresponding to formula wherein A, R, X, Y, R, R1 and R2 are as defined above, pharmaceutical formulations, methods of making and uses thereof.